Litigation Details for Kowa Company, Ltd. v. Sawai USA, Inc. (S.D.N.Y. 2014)

Kowa Company, Ltd. v. Sawai USA, Inc. (S.D.N.Y. 2014)

Docket		Date Filed	2014-07-23
Court	District Court, S.D. New York	Date Terminated	2017-01-26
Cause	35:271 Patent Infringement	Assigned To
Jury Demand	None	Referred To
Patents	6,465,477; 8,557,993
Link to Docket	External link to docket

Details for Kowa Company, Ltd. v. Sawai USA, Inc. (S.D.N.Y. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-07-23				External link to document

Kowa Company, Ltd. v. Sawai USA, Inc. Litigation Summary and Patent Analysis

Last updated: September 29, 2026

Kowa Company, Ltd. sued Sawai USA, Inc. in the U.S. District Court for the Southern District of New York after Sawai filed an abbreviated new drug application seeking approval for a generic version of Livalo, Kowa’s pitavastatin calcium product. The case, 1:14-cv-05575, was a Hatch-Waxman patent dispute. The public docket does not show a trial, claim-construction ruling, or merits judgment. The action ended without a publicly reported adjudication of patent validity or infringement. Public filings do not disclose the material commercial terms of the parties’ resolution.

What drug and FDA pathway were involved in Kowa v. Sawai?

The dispute concerned pitavastatin calcium tablets, the active pharmaceutical ingredient in Livalo. Livalo is an HMG-CoA reductase inhibitor approved by the FDA to reduce elevated low-density lipoprotein cholesterol and treat hyperlipidemia.

Sawai’s ANDA filing triggered Kowa’s infringement action under the Hatch-Waxman Act. Kowa alleged that the proposed generic product would infringe patents listed for Livalo in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book.

Item	Case-specific information
Brand product	Livalo
Active ingredient	Pitavastatin calcium
Brand company	Kowa Pharmaceuticals America, Inc., with Kowa Company, Ltd. as patent owner or related rights holder
Generic applicant	Sawai USA, Inc.
Regulatory pathway	ANDA
Court	U.S. District Court for the Southern District of New York
Civil action	1:14-cv-05575
Dispute type	Hatch-Waxman patent infringement
Public merits outcome	No reported trial or final merits judgment
Public resolution	Case terminated without a reported patent-validity or infringement decision

The case involved a small-molecule generic, not a biologic. Biosimilar approval standards under the Biologics Price Competition and Innovation Act therefore were not applicable.

What patents protected Livalo in Kowa v. Sawai?

Kowa’s complaint asserted Livalo-related patent rights against Sawai’s ANDA product. Publicly available Livalo patent records identify a group of Kowa patents covering pitavastatin compounds, pharmaceutical compositions, and therapeutic uses. The patents most commonly associated with the early Livalo ANDA litigation included U.S. Patent Nos. 6,835,739 and 7,655,630.

The precise patent claims and defenses must be read from the complaint, ANDA notice, and subsequent docket filings. A Hatch-Waxman complaint does not establish that an asserted patent is valid or infringed. It establishes that the patent holder brought an action within the statutory 45-day period after receiving a Paragraph IV notice.

Patent categories relevant to pitavastatin

Kowa’s Livalo estate was directed to several layers of protection:

1. The pitavastatin molecule and related chemical forms.
2. Pitavastatin calcium and pharmaceutical compositions.
3. Tablet formulations and manufacturing characteristics.
4. Methods of treating hyperlipidemia and lowering cholesterol.
5. Later-issued patents that could affect generic launch timing even after earlier compound patents expired.

The commercial value of each patent depended on claim scope, Orange Book listing status, patent-term adjustment or extension, and whether the claims covered the exact strength and formulation described in Sawai’s ANDA.

When did Sawai’s Paragraph IV challenge create litigation risk?

Sawai’s ANDA challenge created a statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to statutory exceptions. The stay is triggered when the NDA holder or patent owner receives notice of a Paragraph IV certification and files an infringement action within 45 days.

The litigation therefore had two immediate consequences:

• FDA approval of Sawai’s ANDA could be delayed during the statutory stay.
• Kowa obtained an opportunity to enforce listed patents before generic approval and commercial launch.

A Paragraph IV certification is an allegation by the ANDA applicant that an Orange Book-listed patent is invalid, unenforceable, or would not be infringed by the proposed generic product. It is not a judicial finding that the patent is defective.

What was the procedural status of Kowa v. Sawai?

The action did not produce a publicly reported trial judgment. There is no widely reported opinion in the case resolving claim construction, patent validity, inequitable conduct, or infringement.

The publicly observable procedural profile is consistent with a Hatch-Waxman case that ended through dismissal or settlement before final adjudication. The docket does not provide a publicly reported explanation establishing the commercial terms of the resolution, the agreed generic launch date, or whether Sawai received an authorized-generic arrangement.

Litigation issue	Publicly reported outcome
Claim construction	No reported substantive Markman ruling
Invalidity	No reported final adjudication
Noninfringement	No reported final adjudication
Inequitable conduct	No reported final adjudication
Trial	None publicly reported
Settlement terms	Not publicly disclosed in the reported docket record
Generic launch date	Not established by a reported merits order
Patent-term ruling	None publicly reported

Did Kowa v. Sawai establish that the Livalo patents were valid?

No. The case did not generate a reported merits decision that would establish the validity or enforceability of the asserted Livalo patents.

This distinction matters for risk analysis. A settlement or dismissal can preserve the patent holder’s commercial position without testing the patent claims. It also does not create binding precedent for other ANDA applicants. Other generic companies could continue to challenge the same patents through separate litigation, subject to the effect of any later court decisions, settlement agreements, or regulatory developments.

What was the commercial significance of the litigation?

The dispute protected Kowa’s ability to delay or control generic entry for pitavastatin calcium. The economic value of that protection depended on several factors:

• The number of remaining Orange Book patents.
• The expiration dates and any patent-term extension.
• The existence of non-Orange Book formulation or process patents.
• The timing of FDA approval for Sawai’s ANDA.
• The terms of any negotiated generic launch.
• The degree of substitution by competing statins, including atorvastatin, rosuvastatin, and simvastatin.

Pitavastatin competes in a crowded statin market. Even a successful patent action would not necessarily preserve brand-level pricing once multiple generic statins were available. The relevant commercial exposure was the remaining Livalo revenue during the period before generic entry, not the total value of the broader statin market.

Kowa’s litigation strategy was therefore likely directed at extending the effective exclusivity period for pitavastatin calcium and controlling the timing of generic competition. The absence of a merits ruling reduced litigation precedent but did not eliminate the commercial value of the settlement or dismissal.

How strong was the Livalo patent estate?

The estate had layered protection, which generally improves settlement leverage compared with a single-patent portfolio. Compound and active-ingredient claims can present a greater barrier to generic entry than narrow method-of-use claims because they may cover the product itself. Formulation and process claims can be more vulnerable to design-around arguments if the ANDA product uses a different excipient profile, manufacturing sequence, crystal form, or dosage configuration.

The practical strength of the estate depended on claim breadth and the exact ANDA formulation. Without a final opinion, the following conclusions are supportable:

• Kowa had sufficient listed patent rights to bring a statutory Hatch-Waxman action.
• The case created a regulatory approval delay for Sawai.
• No public decision confirmed that the asserted patents would survive invalidity or noninfringement challenges.
• The resolution preserved uncertainty for other generic applicants.
• The estate’s strongest commercial value likely came from blocking or postponing launch rather than from a judicially tested precedent.

What was the Orange Book status of Livalo?

Livalo’s Orange Book listings were the regulatory foundation for Kowa’s suit. Listed patents can support a Paragraph IV action when an ANDA applicant challenges them. The Orange Book does not determine whether a patent is valid, enforceable, or infringed. It records patent information submitted by the NDA holder and accepted for listing under FDA rules.

Orange Book analysis should distinguish among:

• Drug-substance patents.
• Drug-product or formulation patents.
• Method-of-use patents.
• Patent expiration dates.
• Pediatric exclusivity.
• Patent-term extension or adjustment.
• Delisting or correction events.

The relevant status can change over time. Current Orange Book records should therefore be compared with the listings in effect when Sawai filed its ANDA and when Kowa initiated the action. The FDA’s Orange Book remains the controlling regulatory source for listed-patent information, while the USPTO and court docket provide the controlling sources for patent prosecution and litigation history (FDA, n.d.; USPTO, n.d.).

Did the case involve licensing, settlement, or authorized-generic rights?

The public record does not disclose material settlement terms. No reported order establishes that Kowa granted Sawai a license, authorized-generic supply rights, co-promotion rights, or a defined early-entry date.

For Hatch-Waxman settlements, the most important undisclosed terms often include:

• The first permitted commercial launch date.
• Whether launch is contingent on patent invalidation.
• Whether Kowa may launch an authorized generic.
• Supply or manufacturing arrangements.
• Acceleration provisions tied to third-party generic entry.
• Payments or other forms of value transfer.
• Covenants not to sue under later-issued patents.

The absence of published terms prevents a definitive assessment of whether the resolution represented a full patent victory, a negotiated early launch, or a broader commercial collaboration.

What generic entry risks remained after the case ended?

The principal residual risks were:

1. Other ANDA applicants could challenge the same patents.
2. A court in separate litigation could invalidate or narrow an asserted patent.
3. Later Orange Book patents could create additional litigation.
4. Generic entry could occur after the statutory stay or under a negotiated settlement.
5. Multiple approved generics could accelerate price erosion for Livalo.

Because pitavastatin is a small molecule, the primary post-litigation risk was generic substitution rather than biosimilar competition. FDA approval of a generic pitavastatin product would depend on ANDA requirements, including pharmaceutical equivalence, bioequivalence, chemistry and manufacturing controls, labeling, and resolution of applicable patent certifications.

Key Takeaways

• Kowa sued Sawai USA in Southern District of New York case 1:14-cv-05575 over an ANDA for generic pitavastatin calcium.
• The dispute involved Livalo and Kowa’s Orange Book-listed patent rights.
• The case ended without a publicly reported trial or final merits ruling.
• No public decision established that the asserted patents were valid, enforceable, or infringed.
• Settlement or dismissal terms, including any generic launch date, were not publicly reported.
• The case created regulatory and commercial delay risk for Sawai but did not establish binding patent precedent.
• Generic risk remained dependent on other ANDA applicants, patent expiration, later-listed patents, and FDA approval timing.
• Biosimilar analysis was not relevant because pitavastatin is a small-molecule drug.

FAQs About Kowa Company, Ltd. v. Sawai USA, Inc.

What was the product at issue in Kowa v. Sawai?

The product was pitavastatin calcium, marketed by Kowa as Livalo for cholesterol reduction and hyperlipidemia.

Was Sawai allowed to launch generic Livalo?

The reported docket does not establish a definitive launch date or the commercial terms governing Sawai’s entry.

Did Kowa win the patent case?

There was no publicly reported trial judgment declaring Kowa’s patents valid and infringed. The case ended without a reported merits adjudication.

Were the Livalo patents subject to Paragraph IV challenges?

Yes. The action arose from Sawai’s ANDA challenge to patents listed for Livalo, consistent with a Paragraph IV Hatch-Waxman dispute.

Are biosimilars a competitive threat to Livalo?

No. Livalo is a small-molecule drug. Generic-drug approval under the ANDA pathway, rather than biosimilar approval under the BPCIA, is the relevant competitive framework.

References

1. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

2. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355(j).

3. U.S. Patent and Trademark Office. (n.d.). Patent Center. U.S. Department of Commerce.

4. Kowa Company, Ltd. v. Sawai USA, Inc., No. 1:14-cv-05575, U.S. District Court for the Southern District of New York.